Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases

(2016) Bassem Sadek et al.   BEHAVIOURAL BRAIN RESEARCH

Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment

(2016) Morten Skøtt Thomsen et al.   CURRENT PHARMACEUTICAL DESIGN

Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

(2016) William James Deardorff et al.   Expert Review of Neurotherapeutics

Alzheimer's disease

(2016) Philip Scheltens et al.   LANCET

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Lack of support for bexarotene as a treatment for Alzheimer's disease

(2016) Eugene O'Hare et al.   NEUROPHARMACOLOGY

Therapeutic strategies for Alzheimer's disease in clinical trials

(2016) Justyna Godyń et al.   Pharmacological Reports

The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function

(2016) Samuel E. Marsh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein S -Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases

(2016) Tomohiro Nakamura et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

(2016) Francesco Panza et al.   Biomed Research International

Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

(2016) William James Deardorff et al.   Expert Review of Neurotherapeutics

Pharmacokinetics, pharmacodynamics, and safety of the novel bace inhibitor bi1181181 after oral administration of single ascending doses in healthy subjects

(2015) Laurent Nicolas et al.   Alzheimers & Dementia

A single dose of the beta-secretase inhibitor, e2609, decreases CSF bace1 enzymatic activity in cynomolgus monkeys

(2015) Mark Matijevic et al.   Alzheimers & Dementia

Suvn-g3031, an h3 receptor inverse agonist, produces procognitive effects without affecting sleep in preclinical models

(2015) Vijay S. Benade et al.   Alzheimers & Dementia

Improving synaptic plasticity and cognitive function in rodents by the novel phosphodiesterase 9A inhibitor bi 409306

(2015) Holger Rosenbrock et al.   Alzheimers & Dementia

Additional results from a phase ii study to assess the clinical and immunological activity, safety, and tolerability of affitope® ad02 in patients with early Alzheimer’s disease (AD)

(2015) Achim Schneeberger et al.   Alzheimers & Dementia

Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

(2015) Jeff Sevigny et al.   Alzheimers & Dementia

Alzheimer’s Next Chapter

(2015)   CHEMICAL & ENGINEERING NEWS

Syntheses and Evaluation of Asymmetric Curcumin Analogues as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease

(2015) Peng Zhai et al.   Current Alzheimer Research

Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions

(2015) Joel Raskin et al.   Current Alzheimer Research

Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2015) Guoyan Yang et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer's disease

(2015) Rong Xiao   CURRENT TOPICS IN MEDICINAL CHEMISTRY

NME digest

(2015) P. Cole   DRUGS OF THE FUTURE

Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system

(2015) Julie Pradal et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Statins for Treating Alzheimer's Disease: Truly Ineffective?

(2015) Ting Liang et al.   EUROPEAN NEUROLOGY

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)

(2015) David H. Lawson et al.   JOURNAL OF CLINICAL ONCOLOGY

Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression

(2015) Holly C. Hunsberger et al.   JOURNAL OF NEUROCHEMISTRY

A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

(2015) Ulf Neumann et al.   Molecular Neurodegeneration

Pivotal trials for β-secretase inhibitors in Alzheimer's

(2015) Cormac Sheridan   NATURE BIOTECHNOLOGY

Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice

(2015) Orly Weinreb et al.   NEUROBIOLOGY OF AGING

Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability

(2015) George A. Jelinek et al.   NEUROLOGICAL RESEARCH

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

(2015) R. Scott Turner et al.   NEUROLOGY

Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

(2015) Enchi Liu et al.   NEUROLOGY

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

(2015) J. Butchart et al.   NEUROLOGY

Systemic administration of riluzole enhances recognition memory and facilitates extinction of fear memory in rats

(2015) Azusa Sugiyama et al.   NEUROPHARMACOLOGY

Long-term treatment with l-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease

(2015) W.-H. Chiu et al.   NEUROPHARMACOLOGY

Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma

(2015) Ceying Shen et al.   NEUROSCIENCE LETTERS

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

(2015) Elvira Valera et al.   Neurotherapeutics

Amyloid Fibres: Inert End-Stage Aggregates or Key Players in Disease?

(2015) Kevin W. Tipping et al.   TRENDS IN BIOCHEMICAL SCIENCES

Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer’s disease

(2015) M. S. Kukharsky et al.   Zhurnal Nevrologii I Psikhiatrii imeni S S Korsakova

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

(2015) Ilya Chumakov et al.   Scientific Reports

EFFICACY AND SAFETY OF THE ALPHA7 AGONIST ABT-126 AS A MONOTHERAPY TREATMENT IN MILD-TO-MODERATE ALZHEIMER'S DEMENTIA: RESULTS OF A PHASE 2B TRIAL

(2014) Ahmed Othman et al.   Alzheimers & Dementia

Ameliorating Effects of HX106N, a Water-Soluble Botanical Formulation, on Aβ25-35-Induced Memory Impairment and Oxidative Stress in Mice

(2014) Doo Suk Lee et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Cognitive Effects of Statin Medications

(2014) Brendan J. Kelley et al.   CNS DRUGS

An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease

(2014) Raj Shah et al.   Current Alzheimer Research

The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development

(2014) H. Blasco et al.   CURRENT MEDICINAL CHEMISTRY

The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics

(2014) M. Carreiras et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status

(2014) Maria J. Ramirez et al.   DRUGS

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

(2014) Chuanpu Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Combined Treatment with a BACE Inhibitor and Anti-A  Antibody Gantenerumab Enhances Amyloid Reduction in APPLondon Mice

(2014) H. Jacobsen et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial

(2014) David Wilkinson et al.   LANCET NEUROLOGY

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

(2014) Adam L Boxer et al.   LANCET NEUROLOGY

Targeting the β secretase BACE1 for Alzheimer's disease therapy

(2014) Riqiang Yan et al.   LANCET NEUROLOGY

AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration

(2014) Robert Alexander et al.   NEUROBIOLOGY OF AGING

Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

(2014) Bonnie C. Shaddinger et al.   PLoS One

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer’s Disease?

(2014) Zhong Ming Qian et al.   Frontiers in Aging Neuroscience

Novel taxanes

(2013) Franco Muggia et al.   ANTI-CANCER DRUGS

Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

(2013) Chieh-Hsin Lin et al.   BIOLOGICAL PSYCHIATRY

Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments

(2013) Jia Yao et al.   BRAIN RESEARCH

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Review article What causes alzheimer’s disease?

(2013) Richard A. Armstrong   FOLIA NEUROPATHOLOGICA

Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial

(2013) H. Davtyan et al.   JOURNAL OF NEUROSCIENCE

Safety and efficacy of ORM-12741 on cognitive and behavioral symptoms in patients with Alzheimer's disease: A randomized, double-blind, proof-of-concept study

(2013) J.O. Rinne et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β–induced deficits in long-term potentiation in the hippocampal CA1 subfield

(2013) Yusaku Takamura et al.   NEUROBIOLOGY OF AGING

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: Protection against impairments in axonal transport

(2013) Yan Jouroukhin et al.   NEUROBIOLOGY OF DISEASE

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

(2013) Valentine Lahmy et al.   NEUROPSYCHOPHARMACOLOGY

Alzheimer disease

(2013) Justin M. Nussbaum et al.   Prion

Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial

(2013) Jorge A. Garcia et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals

(2013) M Bomba et al.   Cell Death & Disease

Comparison of Three Amyloid Assembly Inhibitors: The Sugar scyllo-Inositol, the Polyphenol Epigallocatechin Gallate, and the Molecular Tweezer CLR01

(2012) Sharmistha Sinha et al.   ACS Chemical Neuroscience

A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (IVIG; Octagam® 10%, Octapharma AG) in patients with mild to moderate Alzheimer's disease (GAM10-04)

(2012) Richard Dodel et al.   Alzheimers & Dementia

Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype

(2012) Roger M. Lane et al.   Alzheimers & Dementia

Retinoids for treatment of Alzheimer's disease

(2012) Alan J. Lerner et al.   BIOFACTORS

Ameliorative Effects of Telmisartan on the Inflammatory Response and Impaired Spatial Memory in a Rat Model of Alzheimer^|^#8217;s Disease Incorporating Additional Cerebrovascular Disease Factors

(2012) Taro Shindo et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Tamibarotene: A Candidate Retinoid Drug for Alzheimer’s Disease

(2012) Hiroshi Fukasawa et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine - searching for the connections

(2012) Wojciech Danysz et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment

(2012) Orly Weinreb et al.   CURRENT DRUG TARGETS

Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease

(2012) Fei Li et al.   CURRENT PHARMACEUTICAL DESIGN

Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer’s Disease

(2012) Maria Eriksdotter-Jönhagen et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis

(2012) Jin Hee Shin et al.   JOURNAL OF NEUROCHEMISTRY

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

(2012) Maria L Maccecchini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits

(2012) X.-K. Tong et al.   JOURNAL OF NEUROSCIENCE

Drug repositioning for Alzheimer's disease

(2012) Anne Corbett et al.   NATURE REVIEWS DRUG DISCOVERY

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model

(2012) P. E. Sanchez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ApoE-Directed Therapeutics Rapidly Clear  -Amyloid and Reverse Deficits in AD Mouse Models

(2012) P. E. Cramer et al.   SCIENCE

Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose

(2012) Xiao-Jing Sun et al.   Neuroscience Bulletin

Identification of Exebryl-1® and other novel small molecules as tau protein aggregation inhibitors

(2011) Qubai Hu et al.   Alzheimers & Dementia

Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice

(2011) Yoko Furukawa-Hibi et al.   BEHAVIOURAL BRAIN RESEARCH

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

(2011) Salvatore Salomone et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease

(2011) Kazumasa Kume et al.   Geriatrics & Gerontology International

Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases

(2011) David T. Hickman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease

(2011) Eugenio Barone et al.   JOURNAL OF NEUROCHEMISTRY

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

(2011) Merit Cudkowicz et al.   NATURE MEDICINE

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

(2011) M. Sano et al.   NEUROLOGY

Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin

(2011) T. Kurata et al.   NEUROSCIENCE

Influence of isotretinoin on hippocampal-based learning in human subjects

(2011) Anthony D. Ormerod et al.   PSYCHOPHARMACOLOGY

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

(2011) François Piette et al.   Alzheimers Research & Therapy

Preclinical and early clinical studies of AVN-101, a novel balanced molecule for the treatment of Alzheimer's disease

(2010) Yan Lavrovsky et al.   Alzheimers & Dementia

The Revitalized Tau Hypothesis on Alzheimer's Disease

(2010) Ricardo B. Maccioni et al.   ARCHIVES OF MEDICAL RESEARCH

Transthyretin amyloidoses: New strategies for therapeutic intervention

(2010) O.B. Suhr et al.   DRUGS OF THE FUTURE

SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study

(2010) Gareth Maher-Edwards et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau vaccine: Active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy

(2009) Michal Novak   Alzheimers & Dementia

Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer’s disease

(2009) Katy A. Chalmers et al.   JOURNAL OF NEUROLOGY

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

(2009) Kurt R. Brunden et al.   NATURE REVIEWS DRUG DISCOVERY

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

(2009) Tomohiko Sato et al.   NEUROBIOLOGY OF AGING

Modern approaches to the design of memory and cognitive function stimulants based on AMPA receptor ligands

(2009) V V Grigoriev et al.   RUSSIAN CHEMICAL REVIEWS

Neurobiology ofAlzheimer′s disease

(2009) E Mohandas et al.   Indian Journal of Psychiatry

Amyloid-cholinesterase interactions

(2008) Nibaldo C. Inestrosa et al.   FEBS Journal

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING